@article{10.1371/journal.pone.0027622, doi = {10.1371/journal.pone.0027622}, author = {Kissling, Esther AND Valenciano, Marta AND Cohen, Jean Marie AND Oroszi, Beatrix AND Barret, Anne-Sophie AND Rizzo, Caterina AND Stefanoff, Pawel AND Nunes, Baltazar AND Pitigoi, Daniela AND Larrauri, Amparo AND Daviaud, Isabelle AND Horvath, Judit Krisztina AND O'Donnell, Joan AND Seyler, Thomas AND Paradowska-Stankiewicz, Iwona Anna AND Pechirra, Pedro AND Ivanciuc, Alina Elena AND Jiménez-Jorge, Silvia AND Savulescu, Camelia AND Ciancio, Bruno Christian AND Moren, Alain}, journal = {PLOS ONE}, publisher = {Public Library of Science}, title = {I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe}, year = {2011}, month = {11}, volume = {6}, url = {https://doi.org/10.1371/journal.pone.0027622}, pages = {1-11}, abstract = {Background In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Methods Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination. Results We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ≥60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B. Conclusions Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.}, number = {11}, }